A Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Safety, Tolerability and Efficacy of XEN1101 as Adjunctive Therapy in Focal-onset Epilepsy Save

Date Added
March 26th, 2019
PRO Number
Pro00085211
Researcher
Ekrem Kutluay

List of Studies


Profiles_link
Keywords
Epilepsy
Summary

This study is to evaluate how safe the study drug XEN1101 is for patients with focal epilepsy when it is taken with the patients standard epileptic medications.

This investigational drug has been tested in healthy volunteers but this is the first time it will be tested in participants with focal-onset epilepsy. The study will last about 24 weeks and participants will need to visit the research clinic at least 10 times during the study. Visits will be approximately every 2 weeks, after the first two weekly visits folllowing the start of study treatment.

Institution
MUSC
Recruitment Contact
Robin Bulgarino
843-792-1115
Bulgarino@musc.edu

Change_preferences

-- OR --

Create_login